Impact Factor 5.091 | CiteScore 4.1
More on impact ›

GENERAL COMMENTARY article

Front. Med., 17 January 2022 | https://doi.org/10.3389/fmed.2021.831449

Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

An Expression of Concern on
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

by McCoy, J., Goren, A., Cadegiani, F. A., Vaño-Galván, S., Kovacevic, M., Situm, M., Shapiro, J., Sinclair, R., Tosti, A., Stanimirovic, A., Fonseca, D., Dorner, E., Onety, D. C., Zimerman, R. A., and Wambier, C. G. (2021). Front. Med. 8:668698. doi: 10.3389/fmed.2021.668698

With this notice, Frontiers states its awareness of serious complaints regarding this article. This expression of concern has been posted while Frontiers investigates the allegations. The situation will be updated as soon as the investigation is complete.

Citation: Frontiers Editorial Office (2022) Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front. Med. 8:831449. doi: 10.3389/fmed.2021.831449

Received: 08 December 2021; Accepted: 13 December 2021;
Published: 17 January 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, editorial.office@frontiersin.org